Anti-CLDN18.2 antibody - CS Bay Therapeutics
Latest Information Update: 14 Jul 2022
At a glance
- Originator CS-Bay Therapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Claudin 18 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 28 Jun 2022 Preclinical trials in Cancer in USA (unspecified route) (CS Bay Therapeutics pipeline, June 2022)
- 28 Jun 2022 CS Bay Therapeutics plans a phase I trial in Cancer in USA (unspecified route) (CS Bay Therapeutics pipeline, June 2022)